12.61USD-2.63%Mkt Cap: 1.11B USDP/E: —Last update: 2026-06-01
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.11B USD
Enterprise Value650.72M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-162.45M USD
Revenue/Share—
Last Price12.61 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees137
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.67
PEG—
EV/EBITDA-3.40
EV/Revenue—
P/S—
P/B2.24
EPS (TTM)-2.03
EPS (Forward)-2.33
52W Range
3.89027% of range36.26
52W High36.26 USD
52W Low3.890 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-33.95%
ROA-30.45%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-146.72M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-7.12%
Net Debt-501.39M USD
Net Debt/EBITDA2.62
Balance Sheet
Debt/Equity0.01
Current Ratio10.88
Quick Ratio10.79
Book Value/Sh5.881 USD
Cash/Share5.785 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)41.82 USD
Target Range23.00 USD – 62.00 USD
# Analysts11
Ownership
Shares Out.87.35M
Float59.37M
Insiders1.80%
Institutions119.41%
Short Interest
Short Ratio12.1d
Short % Float16.12%
Short % Out.13.27%
Shares Short11.59M
Short (prev mo.)12.93M
Technical
SMA 5014.74 (-14.5%)
SMA 20016.69 (-24.5%)
Beta2.06
S&P 52W Chg27.94%
Avg Vol (30d)965.23K
Avg Vol (10d)1.12M
Technical Indicators
RSI (14)36.7
MACD-0.6508
MACD Signal-0.6213
MACD Hist.-0.0295
BB Upper15.49 USD
BB Middle13.92 USD
BB Lower12.35 USD
BB Width22.52%
ATR (14)0.8294 USD
Vol Ratio (20d)0.66x